Central Alerting System: Publication of an Interim Clinical Commissioning Policy: Remdesivir for Patients Hospitalised with COVID-19 (adults and children of 12 years and older) 6 July 2020

Royal College of Anaesthetists
Royal College of Anaesthetists (RCoA);Intensive Care Society;Association of Anaesthetists;Faculty of Intensive Care Medicine
Publication date:
06 July 2020


Following confirmation of a Conditional Marketing Authorisation (CMA) by the European Medicines Agency (EMA) for the use of remdesivir in the treatment of COVID-19, the scientific opinion given for remdesivir via the Early Access to Medicines Scheme (EAMS) put in place on 26 May 2020 has now lapsed.

From 3 July 2020, an interim clinical commissioning policy has been put in place to define routine access to remdesivir in the treatment of COVID-19 across the UK. The policy reflects the conditions of the CMA, but also includes secondary criteria to be used should there be limitations in the supply of remdesivir in the UK.